[
  {
    "ts": "2026-01-28T01:04:51+00:00",
    "headline": "Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?",
    "summary": "AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...",
    "url": "https://finance.yahoo.com/news/does-abbvies-bispecific-trial-win-010451665.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7d700956-a51b-34e1-bb55-cd73897ba4f0",
      "content": {
        "id": "7d700956-a51b-34e1-bb55-cd73897ba4f0",
        "contentType": "STORY",
        "title": "Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?",
        "description": "",
        "summary": "AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...",
        "pubDate": "2026-01-28T01:04:51Z",
        "displayTime": "2026-01-28T01:04:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-abbvies-bispecific-trial-win-010451665.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-abbvies-bispecific-trial-win-010451665.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GMAB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]